Atea Pharmaceuticals Inc Stock

$3.33

1.22% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Atea Pharmaceuticals Inc Stock price

$3.33

-27.01 89.02% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.04 1.22%

ISIN

US04683R1068

Symbol

AVIR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$281.26m
Enterprise Value	$-199.71m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.57
P/B ratio (TTM) P/B ratio	0.61
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-200.50m
Free Cash Flow (TTM) Free Cash Flow	$-126.94m
Cash position	$482.81m
EPS (TTM) EPS	$-2.07
P/E forward	negative
Short interest	4.34%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Atea Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Atea Pharmaceuticals Inc forecast:

2x Buy

50%

1x Hold

25%

1x Sell

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Atea Pharmaceuticals Inc forecast:

Buy

50%

Hold

25%

Sell

25%

Analyst Estimates with Stock Price Targets

Financial data from Atea Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.42 0.42	0% 0% -
Gross Profit	-0.42 -0.42	0% 0% -
- Selling and Administrative Expenses	46 46	7% 7% -
- Research and Development Expense	153 153	44% 44% -
EBITDA	-200 -200	27% 27% -
- Depreciation and Amortization	0.42 0.42	0% 0% -
EBIT (Operating Income) EBIT	-200 -200	27% 27% -
Net Profit	-174 -174	33% 33% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Atea Pharmaceuticals Inc Stock News

Neutral

Business Wire

●

10 days ago

Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the “Concerned Shareholder Group” or “we”), who collectively own approximately 3% of the outstanding shares of Atea Pharmaceuticals (NASDAQ: AVIR) (“Atea” or the “Company”), today issued the following open letter to the Company's Board of Directors: *** D...

Neutral

GlobeNewsWire

●

13 days ago

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has engaged Evercore, a global independent investment bank, to identify potential opportunities to enhance shareholder value, i...

Neutral

GlobeNewsWire

●

25 days ago

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration

More Atea Pharmaceuticals Inc News

Company Profile

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Head office	United States
CEO	Jean-Pierre Sommadossi
Employees	75
Founded	2012
Website	www.ateapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now